Adlai Nortye Ltd. has entered into an exclusive licensing agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (Ask Pharm) for its proprietary pan-RAS(ON) inhibitor AN-9025, an oral small molecule designed to target a broad spectrum of RAS mutations across various tumor types.
Ipsen SA has signed an exclusive licensing agreement with Simcere Zaiming Pharmaceutical Co. Ltd. for global rights outside of Greater China for SIM-0613, an LRRC15-targeting antibody-drug conjugate developed by Simcere Zaiming for solid tumors. The program is expected to enter phase I development in the second half of next year.
Tonix Pharmaceuticals Holding Corp. has licensed exclusive worldwide rights to TNX-4900 (formerly PW-507) from Rutgers University. TNX-4900 is a highly selective, small-molecule sigma-1 receptor (S1R) antagonist, which has demonstrated analgesic activity in multiple models of neuropathic pain.
Taigen Biotechnology Co. Ltd. and its Taigen Biopharmaceuticals subsidiary have entered into an exclusive in-licensing agreement with Insilico Medicine Inc. for ISM-4808, a prolyl hydroxylase domain (PHD) inhibitor.
Toolgen Inc. has entered into a strategic cross-license agreement with Geneditbio Ltd. to jointly advance the development of next-generation in vivo genome-editing therapeutics.
Mwyngil Therapeutics Inc. has in-licensed several lead GPR75 modulator molecules and a proprietary cell-surface discovery platform from Expert Systems Inc.
Transthera Sciences Inc. is out-licensing one of its preclinical NLRP3 inhibitors to Neurocrine Biosciences Inc. under a collaboration agreement worth $881.5 million. Under deal terms, Nanjing, China-based Transthera will receive an undisclosed up-front payment and is eligible to receive research and development and sales-based milestone payments up to $881.5 million.
Boehringer Ingelheim Pharma GmbH & Co KG and CDR-Life Inc. have entered into a new global licensing agreement to develop CDR-111 for autoimmune diseases.
Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for two of Kaigene’s nonclinical-stage assets, KG-006 and KG-002. Kaigene’s pipeline leverages its technology to selectively degrade pathogenic antibodies that mainly exacerbate various autoimmune diseases.
Boehringer Ingelheim GmbH and Kyowa Kirin Co. Ltd. have announced that Boehringer Ingelheim has licensed a preclinical program from Kyowa Kirin to develop a potential first-in-class, small molecule for the treatment of autoimmune diseases.
RSS
